VEGFA and fetal growth restriction: Angiogenesis inhibitors such as bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) antibody, are teratogenic and induce intrauterine growth restriction (IUGR), pregnancy loss and skeletal malformation in animal models (mice and rats).